OncoSystem Directory
Explore organizations in the global Oncology ecosystem
724 organization(s) found
Hospital of the University of Pennsylvania - Penn Presbyterian
Philadelphia, PA, United States
WebsiteIARC (International Agency for Research on Cancer)
IARC’s Mission: Cancer research for cancer prevention. The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of IARC is to promote international collaboration in cancer research. The Agency is interdisciplinary, bringing together skills in epidemiology, laboratory sciences, and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the Agency is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. IARC has a particular interest in conducting research in low- and middle-income countries through partnerships and collaborations with researchers in these regions.
Cancer Research & Control Lyon, France WebsiteIARC‑linked Chinese Cancer Surveillance Network (via various regional registries)
A nationwide network of regional cancer registries contributing data to international bodies like International Agency for Research on Cancer (IARC). Through this network, Chinese cancer incidence, mortality and epidemiologic data get systematically collected and shared. (publications.iarc.who.int)
Multiple cities, China WebsiteIASLC (International Association for the Study of Lung Cancer)
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries. By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.
WebsiteIASO Bio
Founded in 2017, IASO Bio is among the few commercial-stage biopharmaceutical companies in the Advanced Therapy Medicinal Product (ATMP) sector bringing Chinas breakthrough innovations to the global market. We specialize in developing cell therapies and biologics for hematological malignancies and autoimmune diseases. Our industry-leading, fully integrated platforms leverage cutting-edge technologies across the product lifecycle, from discovery & development to manufacturing & commercialization.
Hemato-Oncology, Hematology, Autoimmunity Pleasanton, CA, United States WebsiteICC (Ivory Coast Cancer Center)
Provides cancer treatment, research, and training in Côte d’Ivoire.
Abidjan, Ivory Coast WebsiteIC–OS (International Cardio–Oncology Society)
The International Cardio-Oncology Society is committed to raising awareness about cardiovascular disease that commonly occurs in patients undergoing treatment for cancer. The ongoing success and complexity of current life-saving therapies has led to the recognition by healthcare providers, patients, and caregivers that cardiac health is vitally important in order to obtain the best patient outcomes. We aim to enhance recognition among providers that prevention and early detection of cardiovascular disease is essential to providing optimal protection for our patients.
Tampa, FL, United States WebsiteICPO (International Centers for Precision Oncology) Foundation
The International Centers for Precision Oncology (ICPO) Foundation is a nonprofit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Cancer is one of the most significant health challenges of our time and the need for more effective treatments is pressing. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation´s aim is to gain momentum for Radiotheranostics in cancer care worldwide and scale global patient access to this innovative therapy. Radiomolecular Precision Oncology is a highly targeted therapy with low side effects, improved efficacy and patient outcomes. The ICPO Foundation is establishing an international collaborative network of accredited ICPO Theranostics Centers of Excellence by sharing knowledge, standards and education in Radiomolecular Precision Oncology.
WebsiteIDEAYA Biosciences
IDEAYA is a clinical-stage precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality � an emerging class of precision medicine targets.
Precision medicines based on synthetic lethality for treatment of solid tumors South San Francisco, CA, United States WebsiteIEO (European Institute of Oncology)
The IEO (European Institute of Oncology) is one of the world's most prestigious hospitals and the fastest growing comprehensive cancer centre in Europe. IEO integrates the various areas related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research. Mission & Values: The European Institute of Oncology (Istituto Europeo di Oncologia - IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.
Cancer Care & Research Milan, Italy WebsiteIksuda Therapeutics
The ADC field continues to grow as ongoing technology innovations address past shortcomings for an improved probability of success. Iksuda is at the forefront of this, developing class leading ADCs based on selecting the most clinically relevant combination of binder, conjugation chemistry, linker and payload mechanism. Our best-in-class clinical-stage ADCs validate the tumor-selective payload activation approach, which we continue to innovate. Our expanding early-stage ProAlk-ADC pipeline will offer new treatment choices for hard-to-treat cancers and help to address ADC sequencing � a major development challenge in the future.
ADCs for Oncology (solid tumors and blood cancers) Newcastle, United Kingdom Website